• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

索拉非尼和WH-4联合治疗可相加性抑制肝癌细胞的增殖。

Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells.

作者信息

Chen Su-Hong, Xu Dan-Dan, Zhou Peng-Jun, Wang Yao, Liu Qiu-Ying, Ren Zhe, Liu Zhong, Wang Xia, Huang Hui-Qing, Xue Xue, Wang Ying, Wang Yi-Fei

机构信息

College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, P.R. China.

College of Biotechnology, Guangdong Food and Drug Vocational College, Guangzhou, Guangdong 510520, P.R. China.

出版信息

Exp Ther Med. 2022 Mar;23(3):232. doi: 10.3892/etm.2022.11156. Epub 2022 Jan 20.

DOI:10.3892/etm.2022.11156
PMID:35222709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8815050/
Abstract

Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and wh-4 on the proliferation of liver cancer cells was investigated. The results showed that sorafenib with wh-4 additively suppressed the proliferation of liver cancer cells. The colony formation of liver cancer cells decreased significantly in response to the combination treatment of sorafenib with wh-4, and it also induced the apoptosis of liver cancer cells. Western blot analysis demonstrated decreased expression of Bcl2, and increased expression of Bax in liver cancer cells treated with a combination of sorafenib and wh-4. Moreover, the migration of liver cancer cells was inhibited. The combination treatment of sorafenib with wh-4 reduced the expression levels of and which are responsible for resistance. Finally, STAT3 overexpression abolished the proliferation inhibition effect of sorafenib with wh-4 on liver cancer cells, and sorafenib and wh-4 suppressed the proliferation of liver cancer cells by STAT3 pathway. Together, these results suggest that sorafenib-wh4 combination treatment is a potential novel therapeutic approach to suppress the proliferation of liver cancer cells.

摘要

索拉非尼目前用于治疗肝细胞癌（HCC）。然而，对索拉非尼产生化疗耐药性是索拉非尼用于HCC患者治疗的主要限制。在本研究中，研究了索拉非尼与wh-4联合治疗对肝癌细胞增殖的影响。结果表明，索拉非尼与wh-4联合使用可加成性抑制肝癌细胞的增殖。索拉非尼与wh-4联合治疗后，肝癌细胞的集落形成显著减少，并且还诱导了肝癌细胞的凋亡。蛋白质印迹分析表明，索拉非尼与wh-4联合处理的肝癌细胞中Bcl2表达降低，Bax表达增加。此外，肝癌细胞的迁移受到抑制。索拉非尼与wh-4联合治疗降低了与耐药相关的 和 的表达水平。最后，STAT3过表达消除了索拉非尼与wh-4对肝癌细胞的增殖抑制作用，并且索拉非尼和wh-4通过STAT3途径抑制肝癌细胞的增殖。总之，这些结果表明索拉非尼-wh4联合治疗是一种潜在的抑制肝癌细胞增殖的新型治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/eaf55b4ec27c/etm-23-03-11156-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/0ab4b7ca5119/etm-23-03-11156-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/03d9796c68c9/etm-23-03-11156-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/f1f25f87396e/etm-23-03-11156-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/d3bd722bcb95/etm-23-03-11156-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/8eaa7f7935a2/etm-23-03-11156-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/eaf55b4ec27c/etm-23-03-11156-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/0ab4b7ca5119/etm-23-03-11156-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/03d9796c68c9/etm-23-03-11156-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/f1f25f87396e/etm-23-03-11156-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/d3bd722bcb95/etm-23-03-11156-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/8eaa7f7935a2/etm-23-03-11156-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef37/8815050/eaf55b4ec27c/etm-23-03-11156-g05.jpg

相似文献

1
Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells.索拉非尼和WH-4联合治疗可相加性抑制肝癌细胞的增殖。
Exp Ther Med. 2022 Mar;23(3):232. doi: 10.3892/etm.2022.11156. Epub 2022 Jan 20.
2
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.YC-1通过抑制肝细胞癌中的信号转导和转录激活因子3（STAT3）增强索拉非尼的抗肿瘤活性。
Mol Cancer. 2014 Jan 13;13:7. doi: 10.1186/1476-4598-13-7.
3
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.新型双重 PI3K/mTOR 抑制剂 CMG002 单独及联合索拉非尼在肝癌中的临床前疗效。
Cancer Chemother Pharmacol. 2019 Oct;84(4):809-817. doi: 10.1007/s00280-019-03918-y. Epub 2019 Aug 5.
4
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.载sorafenib 和米非司酮的 CXCR4 靶向 PLGA-PEG 纳米粒共递送克服了肝细胞癌对 sorafenib 的耐药性。
J Exp Clin Cancer Res. 2019 May 31;38(1):232. doi: 10.1186/s13046-019-1216-x.
5
Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.新型巴比妥酸衍生物治疗对肝癌索拉非尼耐药具有抗增殖和抗迁移作用。
Molecules. 2020 Jun 20;25(12):2856. doi: 10.3390/molecules25122856.
6
Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27 signaling pathway.普瑞巴林通过调节 Akt/FoxO1/p27 信号通路，通过内质网应激和 ROS 生成，协同增敏条件重编程的患者来源原发性肝癌细胞对索拉非尼的敏感性。
Phytomedicine. 2021 Jun;86:153563. doi: 10.1016/j.phymed.2021.153563. Epub 2021 Apr 4.
7
Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.索拉非尼和青蒿琥酯在肝癌细胞中的协同抗肿瘤活性。
Acta Pharmacol Sin. 2020 Dec;41(12):1609-1620. doi: 10.1038/s41401-020-0395-5. Epub 2020 Apr 16.
8
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.SC-2001通过激活肝细胞癌中的RFX-1/SHP-1克服STAT3介导的索拉非尼耐药性。
Neoplasia. 2014 Jul;16(7):595-605. doi: 10.1016/j.neo.2014.06.005. Epub 2014 Jul 18.
9
Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.SLC46A3 的高表达可抑制肝细胞癌的进展及其对索拉非尼治疗的影响。
Biomed Pharmacother. 2019 Jun;114:108864. doi: 10.1016/j.biopha.2019.108864. Epub 2019 Apr 10.
10
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.索拉非尼联合水飞蓟宾通过增强抑制 STAT3/ERK/AKT 的磷酸化作用，协同靶向 HCC 细胞和肿瘤干细胞。
Eur J Pharmacol. 2018 Aug 5;832:39-49. doi: 10.1016/j.ejphar.2018.05.027. Epub 2018 May 19.

本文引用的文献

1
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.肝细胞癌耐药性的分子基础
Cancers (Basel). 2020 Jun 23;12(6):1663. doi: 10.3390/cancers12061663.
2
STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma.信号转导和转录激活因子3：肝细胞癌新出现的治疗靶点
Cancers (Basel). 2019 Oct 25;11(11):1646. doi: 10.3390/cancers11111646.
3
A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.索拉非尼治疗肝移植前肝细胞癌的前瞻性临床试验。
BMC Cancer. 2019 Jun 11;19(1):568. doi: 10.1186/s12885-019-5760-8.
4
Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment.索拉非尼治疗后晚期肝细胞癌二线治疗候选方案（包括瑞戈非尼和雷莫西尤单抗）的临床特征与结局
Hepatol Res. 2019 Sep;49(9):1054-1065. doi: 10.1111/hepr.13358. Epub 2019 May 29.
5
Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.探讨肝细胞癌的新治疗选择：索拉非尼联合地衣酸。
J Pharm Pharmacol. 2019 Jul;71(7):1119-1132. doi: 10.1111/jphp.13097. Epub 2019 Apr 25.
6
Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells.蛋白质生物合成是索拉非尼的一个靶点，它干扰肝癌细胞中的未折叠蛋白反应（UPR）和铁死亡。
Oncotarget. 2018 Jan 3;9(9):8400-8414. doi: 10.18632/oncotarget.23843. eCollection 2018 Feb 2.
7
ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma.ABC 转运蛋白：在肝癌和结直肠癌中的多药耐药性的调节和关联。
Curr Med Chem. 2019;26(7):1224-1250. doi: 10.2174/0929867325666180105103637.
8
Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.法尼基转移酶抑制剂洛那法尼与化疗药物联合对肝癌细胞生长的协同作用。
Oncotarget. 2017 Oct 26;8(62):105047-105060. doi: 10.18632/oncotarget.22086. eCollection 2017 Dec 1.
9
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).一项紫杉醇单药与紫杉醇联合索拉非尼二线和三线治疗人表皮生长因子受体 2 阴性转移性乳腺癌（PASO）的随机 II 期研究。
BMC Cancer. 2017 Jul 25;17(1):499. doi: 10.1186/s12885-017-3492-1.
10
Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression.癌细胞分泌的 IGF2 可促使成纤维细胞和骨髓来源的血管祖细胞促进肿瘤进展。
Nat Commun. 2017 Feb 10;8:14399. doi: 10.1038/ncomms14399.